Nav: Home

Using drugs for different diseases than initially intended for

November 29, 2016

One drug, one disease.

This is how we traditionally think about pharmaceutical drugs, but many of them are actually effective for more than one disease.

Take the drug gabapentin, originally developed for treating epilepsia, but today commonly prescribed as a pain killer. Or sildenafil, originally developed for treating high blood pressure, but today more often used to treat erectile dysfunction.

Value for patients

"With our recent research we predicted yet unknown beneficial effects for many drugs - on different diseases than they were initially developed for. This is of immense value, both for patients and for the pharmaceutical industry - in particular when it comes to avoiding expensive clinical trials on drug safety", says associate professor Jan Baumbach, University of Southern Denmark.

Jan Baumbach is an expert in computational biomedicine and his research focuses on retrieving meaningful information from big data generated nowadays in the health care sector.

Together with his colleagues Peng Sun from the Max-Planck Institute for Informatics in Germany, Jiong Guo from ShanDong University in China, and Rainer Winnenburg from Stanford University in the U.S., Baumbach has used novel big data analytics methods to trawl through massive pharmaceutical data, looking for drugs having a high potential to be what the scientists call "repurposable".

The results are published in the journal Drug Discovery Today.

From inflammatory diseases to Parkinson's

Baumbach's team found ca. thirty thousand "repurposable" drug candidates. Of these ca. eleven thousand have already been mentioned in scientific literature, and about 1,400 are reported in literature as concrete "repurposing" options.

This leaves roughly 19,000 highly confident drug-disease combinations that no one has yet considered to investigate - a huge gold mine for future pharmaceutical research.

One example is prednisone, originally developed to treat inflammatory diseases. This drug turns out to hold promise for treating Parkinson's disease as well. Another example is chlorpromazine, originally developed to treat schizophrenia, but likely to be effective against tuberculosis as well.

Avoiding animal trials

According to Baumbach and his co-authors, the pharmaceutical industry is facing great challenges due to a decreasing speed of new drug discoveries. New approaches are necessary.

"Drug design is extremely expensive, time-consuming and becoming increasingly complicated. Our approach is a way of inferring new purposes of existing drugs computationally - saving a lot of time, money and maybe more important, avoiding potentially dangerous animal and clinical trials", says Baumbach.

In their paper, the researchers write that the development cycle can be reduced through repositioning by as long as five years, compared to traditional drug discovery pipelines, adding:

Reduced safety risk for patients

"Repurposable drugs have significantly reduced safety risks for patients, because already known and registered drugs have been thoroughly studied with respect to their toxicity and possible side-effects."

The total list of the discovered 31,731 candidates is freely available and can be obtained from the researchers or the publication's online supplementary material. The list includes, for instance, a drug used to treat hypertension or one with anti-inflammatory effect given after organ transplantation that might be well suitable for treating certain cancer types.

Side bar: How did they find the candidates?

Computational approaches play an increasingly important part in nowadays pharmaceutical discoveries. In this case, the researchers created a new data model allowing them to mine for shared properties between genes, drugs and diseases, and to combine this novel data structure with an artificial intelligence to mine millions of scientific publications for approving or disproving hints.
-end-
Contact: Jan Baumbach, tel +45 6550-2309. E-mail: jan.baumbach@imada.sdu.dk

Jan Baumbach' s group website: http://www.baumbachlab.net

University of Southern Denmark

Related Clinical Trials Articles:

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
Not enough women included in some heart disease clinical trials
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.
BU: Obese patients underrepresented in cancer clinical trials
A new review by Boston University School of Public Health researchers found that less than one-fifth of participants in cancer-related clinical trials are obese.
Are women really under-represented in clinical trials?
Several studies have reported a lack of gender diversity in clinical trials, with trials including mostly adult males; however, a recent review of publicly available registration data of clinical trials at the US Food and Drug Administration for the most frequently prescribed drug classes found no evidence of any systemic significant under-representation of women.
More Clinical Trials News and Clinical Trials Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.